FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 叮噹健康科技集團有限公司 呈交日期： 2025年11月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09886 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有 ...

格隆汇11月26日丨叮当健康(09886.HK)公告，11月26日耗资18万港元回购17万股。 叮当健康(09886.HK)11月26日耗资18万港元回购17万股 叮当健康(09886.HK)11月25日耗资43万港元回购 41万股 相关事件 ...

智通财经APP讯，叮当健康(09886)发布公告，于2025年11月26日，该公司斥资17.91万港元回购17万 股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 叮噹健康科技集團有限公司 呈交日期： 2025年11月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09886 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有 ...

智通财经APP讯，叮当健康(09886)发布公告，于2025年11月25日该公司斥资43.09万港元回购41万股， 回购价格为每股1.02-1.06港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 叮噹健康科技集團有限公司 呈交日期： 2025年11月25日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09886 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | ...

Core Viewpoint - Dingtang Health is struggling in the competitive internet healthcare market, facing significant losses and lagging behind major competitors like JD Health, Alibaba Health, and Ping An Good Doctor, with cumulative losses exceeding 60 billion yuan since its inception [1][2][5]. Financial Performance - In the first half of 2025, Dingtang Health reported revenue of 2.327 billion yuan, with a shareholder loss of 51.67 million yuan, indicating a slight improvement in losses but still significantly trailing behind competitors [1][4]. - Cumulative losses from 2018 to 2025 amount to approximately 64 billion yuan, with annual losses increasing each year [5][6]. - The company’s revenue growth has been minimal, with a year-on-year increase of only 2.6% in the first half of 2025 [4]. Competitive Landscape - Dingtang Health operates in a highly competitive environment dominated by larger players like JD Health and Alibaba Health, which have established profitable business models and strong market positions [8]. - Competitors have significant advantages in user traffic, financial resources, and supply chain capabilities, making it difficult for Dingtang Health to maintain its market share [8]. Business Model and Operational Challenges - The company's heavy asset and marketing-focused business model has led to high operational costs, which continue to erode profit margins [8][9]. - Dingtang Health has invested heavily in building its own pharmacies and delivery teams to ensure quick service, but this has resulted in substantial ongoing expenses [8]. Market Sentiment and Stock Performance - Dingtang Health's stock price has plummeted by 92% since its IPO, with a current market capitalization of only 1.3 billion HKD [11][12]. - The company has faced numerous customer complaints regarding service quality, particularly related to delivery times, which has further damaged its reputation [14][15].

Core Insights - Dingdang Health has successfully launched the "Online Medical Insurance + Instant Retail" service model in key areas of Hangzhou, marking its expansion in important cities in East China [1] - The service allows insured individuals in Hangzhou to purchase medications online through platforms like Meituan and Ele.me, utilizing their medical insurance accounts for payment [1] - The initial offering includes hundreds of drug varieties, covering both insured and self-paid OTC medications across various common categories [1][2] Company Developments - Dingdang Health has previously implemented online medical insurance payment functions in cities such as Beijing, Shanghai, Shenzhen, Foshan, and Chengdu [1] - The company has established a dedicated team of doctors and pharmacists to provide 24/7 online consultation and medication guidance, enhancing its health service capabilities [1] Industry Trends - The gradual relaxation of medical insurance policies towards new scenarios like instant retail is expected to benefit companies like Dingdang Health, allowing them to expand service boundaries and improve user engagement and market competitiveness [2]

Core Insights - Dingtang Health has launched a new innovative drug, injection Vuxin Qibai monoclonal antibody (brand name: Jinbeixin), which was approved by the National Medical Products Administration in July 2023 for treating acute gouty arthritis in adults who are intolerant to or have contraindications for non-steroidal anti-inflammatory drugs and/or colchicine [1] - The prevalence of hyperuricemia among Chinese adults was reported at 14% from 2018 to 2019, with gout prevalence ranging from 0.86% to 2.20%, indicating a rising trend and younger onset age [1] - The gout medication market in China is projected to exceed 10 billion yuan by 2030 [1] Company Developments - Dingtang Health is actively expanding its innovative drug portfolio, having introduced several innovative drugs under its "New Special Drug Life Ark" plan and "Original Drug Supply Alliance" initiative, enhancing patient access and treatment adherence [1] - The company is enhancing its AI technology development and application, establishing smart warehouses and cold chain delivery services across major regions, and integrating online medical insurance payment systems [2] - For the first half of 2025, Dingtang Health reported revenues of 2.327 billion yuan, a year-on-year increase of 2.6%, with a gross profit of 816 million yuan and a gross margin of 35% [2] - The company narrowed its losses to 52.02 million yuan, a 42.1% improvement compared to the same period in 2024, with adjusted net profit losses reduced by 78.2% [2] - Future strategies include focusing on user lifecycle health management, expanding smart center warehouse construction, and enhancing service capabilities in major cities like Beijing, Shanghai, and Shenzhen [2]

Core Viewpoint - The Hong Kong stock market saw a rise in internet healthcare stocks, with Ping An Good Doctor increasing by over 6%, followed by gains in JD Health, Dingdang Health, and Alibaba Health [1] Group 1 - The internet healthcare sector in Hong Kong is experiencing positive momentum, indicated by the significant rise in stock prices [1] - Ping An Good Doctor's stock price increased by more than 6%, showcasing strong market performance [1] - Other companies in the sector, including JD Health, Dingdang Health, and Alibaba Health, also saw their stock prices rise, reflecting a broader trend in the industry [1]